National Stage of PCT/US2005/07867

Filed : Herewith

AMENDMENTS TO THE CLAIMS:

Claims 1-78 and 82 are pending. Claims 79-81 are cancelled without prejudice or disclaimer. Please amend claims 1-29, 36-51, 56, 58, 59, 61-69, 71-78 and 82 as indicated below. This listing of claims replaces all prior versions, and listings of claims, in the application.

LISTING OF CLAIMS:

1. (Currently amended) A compound having a structure selected from among Formula I, Formula II, Formula IV, Formula V, and Formula VI:

$$R^{3a}$$
 R^{3a}
 R^{8}
 R^{9}
 R^{10}
 R^{5}
 R^{10}
 R^{10}
 R^{10}
 R^{10}
 R^{10}

$$R^{6a}$$
 R^{7a}
 R^{12}
 R^{13}
 R^{2}
 R^{10}
 R^{9}
 R^{10}
 R^{10}
 R^{10}
 R^{10}
 R^{10}
 R^{10}
 R^{10}
 R^{10}
 R^{10}
 R^{10}

$$R^{16}$$
 R^{6}
 R^{7}
 R^{8}
 R^{15}
 R^{14}
 R^{17}
 R^{10}
 R^{10}
 R^{11}
(III)

$$R^{16}$$
 R^{16}
 R^{16}
 R^{16}
 R^{16}
 R^{16}
 R^{16}
 R^{17}
 R^{12}
 R^{13}
 R^{13}
 R^{10}
 R^{19}
 R^{10}
 R^{10}
 R^{10}
 R^{10}
 R^{10}

National Stage of PCT/US2005/07867

Filed : Herewith

$$R^{19}$$
 R^{19}
 R^{19}
 R^{20}
 R^{22}
 R^{23}
 R^{24}
 R^{24}
 R^{21}
 R^{26}
 R^{25}
 R^{25}
 R^{20}

$$R^{19}$$
 R^{19}
 R^{18}
 R^{21}
 R^{25}
 R^{25}
 R^{25}
 R^{25}

wherein:

 R^1 and R^2 are each independently selected from among hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$, $NHCOR^A$, and $NHCONR^AR^B$, provided that at least one of R^1 and R^2 is not hydrogen;

 R^3 , R^{3a} , R^4 , and R^5 are each independently selected from <u>among</u> hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

wherein if R¹ is NO₂ and R^{3a} is F, then at least one of R² and R⁴ and R⁵ is not hydrogen; and wherein if R¹ is NO₂ and R³ is F, then Z is not O;

 R^6 , R^7 , R^{10} , and R^{11} are each independently selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^{6a} and R^{7a} are each independently selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl; or R^{6a} and R^{7a} together form a carbonyl;

 R^8 and R^9 are each independently selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 alkynyl, an optionally

National Stage of PCT/US2005/07867

Filed : Herewith

substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, $CH(R^D)OR^A$, $CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$;

 R^{12} and R^{13} are each independently selected from among hydrogen, F, Cl, OR^A , NR^AR^B , SR^A , an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_2 - C_6 alkynyl, an optionally substituted C_2 - C_6 alkenyl, and $(CH_2)_mR^C$;

R¹⁴ and R¹⁵ are each independently selected from <u>among</u> hydrogen, F, Cl, Br, I, OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, an optionally substituted C₁-C₄ heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B;

 R^{16} and R^{17} are each independently selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

R¹⁸ and R¹⁹ are each independently selected from among hydrogen, F, Cl, Br, I, OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, an optionally substituted C₁-C₄ heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B;

 R^{20} and R^{21} are each independently selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl; wherein if R^{18} is NO_2 and X is O, then at least one of R^{19} , R^{20} , and R^{21} is not hydrogen, and wherein if R^{19} is NO_2 and X is C, then at least one of R^{18} , R^{20} , and R^{21} is not hydrogen;

 R^{22} is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^6 , CO_2R^A , $CONR^AR^B$, SO_2R^A , an optionally substituted aryl, an optionally substituted heteroaryl, $CH_2CH(R^D)OR^A$, $CH_2CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$, wherein the optionally substituted aryl or optionally substituted heteroaryl is optionally substituted with a substituent selected from among F, Cl, Br, I, CN, OR^A , NO_2 , NR^AR^B , SR^A , SOR^A , SO_2R^A , an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl;

 R^{23} and R^{24} are each independently selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_1 - C_8

Applicant: Zhi et al.

Attorney's Docket No.: 18202-028US1 / 1112US

Serial No.: To Be Assigned

Preliminary Amendment

National Stage of PCT/US2005/07867

Filed : Herewith

heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 alkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, $CH(R^D)OR^A$, $CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$; or R^{23} and R^{24} together form a carbonyl group, provided that if R^{18} is NO_2 and X is NH, then R^{23} and R^{24} do not together form a carbonyl group;

R²² and R²³ are optionally linked to form a ring;

R²³ and R²⁵ are optionally linked to form a ring;

X is selected from among O, S, CR^AR^B, NR^D, and a bond; wherein if X is CR^AR^B or a bond, then R²⁵ and R²⁶ are each independently selected from among a halogen, OR^A, NR^AR^B, hydrogen, an optionally substituted C₁-C₈ alkyl, an optionally substituted C₂-C₈ alkenyl, an optionally substituted C₁-C₈ haloalkyl, an optionally substituted C₂-C₈ haloalkenyl, an optionally substituted C₂-C₈ heteroalkenyl, an optionally substituted C₂-C₈ alkynyl, an optionally substituted C₂-C₈ haloalkynyl, an optionally substituted C₂-C₈ heteroalkynyl, an optionally substituted C₂-C₈ heteroalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, and (CH₂)_mR^C; or R²⁵ and R²⁶ together form a carbonyl group;

and wherein if X is selected from among O, S, or NR^D , then R^{25} and R^{26} are each independently selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 alkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted aryl, an optionally substituted aryl, an optionally substituted heteroaryl, and $(CH_2)_mR^C$; or R^{25} and R^{26} together form a carbonyl group;

 R^A and R^B are each independently selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^C is selected from <u>among</u> an optionally substituted aryl and an optionally substituted heteroaryl that is optionally with a substituent selected from <u>among</u> F, Cl, Br, I, CN, OR^A , NO_2 , NR^AR^B , SR^A , SOR^A , SO_2R^A , an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

National Stage of PCT/US2005/07867

Filed: Herewith

 R^D is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

Z is selected from among O, S, CRARB, and NRD;

n is 0, 1, or 2; and

m is 1 or 2; or a pharmaceutically acceptable salt, ester, amide or prodrug thereof.

2. (Currently amended) The compound of claim 1 having Formula II or Formula IV:

$$R^{6a}$$
 R^{7a}
 R^{12}
 R^{13}
 R^{15}
 R^{10}
 R^{10}

wherein

 R^1 and R^2 are each independently selected from <u>among</u> hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$, $NHCOR^A$, and $NHCONR^AR^B$, provided that at least one of R^1 and R^2 is not hydrogen;

 R^3 , R^4 , and R^5 are each independently selected from <u>among</u> hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

wherein if R¹ is NO₂ and R³ is F, then Z is not O;

 R^6 , R^7 , and R^{10} are each independently selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^{6a} and R^{7a} are each independently selected from among hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl; or R^{6a} and R^{7a} together form a carbonyl;

National Stage of PCT/US2005/07867

Filed : Herewith

 R^9 is selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_1 - C_8 haloalkenyl, C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 alkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heterohaloalkenyl, an optionally substituted C_2 - C_8 heterohaloalkynyl, an optionally substituted C_2 - C_8 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, C_1 - C_2 - C_3 - C_4 - C_5 - C_6 - C_6 - C_6 - C_6 - C_6 - C_7 - C_8 -

 R^{12} and R^{13} are each independently selected from among hydrogen, F, Cl, OR^A , NR^AR^B , SR^A , an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, an optionally substituted C_2 - C_6 alkynyl, and $(CH_2)_mR^C$;

R¹⁴ and R¹⁵ are each independently selected from among hydrogen, F, Cl, Br, I, OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, an optionally substituted C₁-C₄ heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B;

 R^{16} and R^{17} are each independently selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

 R^A and R^B are each independently selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^C is selected from <u>among</u> an optionally substituted aryl and an optionally substituted heteroaryl that is optionally with a substituent selected from <u>among</u> F, Cl, Br, I, CN, OR^A , NO_2 , NR^AR^B , SR^A , SOR^A , SO_2R^A , an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^D is selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

Z is selected from among O, S, CRARB, and NRD;

n is 0, 1, or 2; and

m is 1 or 2.

National Stage of PCT/US2005/07867

Filed : Herewith

3. (Currently amended) The compound of claims 1 or 2 claim 1, wherein R¹ is selected from NO₂ and CN.

- 4. (Currently amended) The compound of any of claims 1-3 claim 1, wherein R¹ is NO₂.
- 5. (Currently amended) The compound of any of claims 1-3 claim 1, wherein R¹ is CN.
- 6. (Currently amended) The compound of any of claims 1-5 claim 1, wherein R^2 is an optionally substituted C_1 - C_4 alkyl or an optionally substituted C_1 - C_4 haloalkyl.
- 7. (Currently amended) The compound of any of claims 1-6 claim 1, wherein R^2 is C_1 - C_4 alkyl or trifluoromethyl.
- 8. (Currently amended) The compound of any of claims 1-7 claim 1, wherein R^3 , R^4 , and R^5 are each independently selected from among hydrogen, F, Cl, and an optionally substituted C_1 - C_4 alkyl.
- 9. (Currently amended) The compound of any of claims 1-8 claim 1, wherein R³ is hydrogen.
- 10. (Currently amended) The compound of any of claims 1-8 claim 1, wherein R⁴ is hydrogen.
- 11. (Currently amended) The compound of any of claims 1-8 claim 1, wherein R⁵ is hydrogen.
- 12. (Currently amended) The compound of any of claims 1-11 claim 1, wherein R^{6a} and R^{7a} are each independently selected from among hydrogen, an optionally substituted C_1 - C_6 alkyl, and an optionally substituted C_1 - C_6 heterohaloalkyl or R^{6a} and R^{7a} together form a carbonyl.
- 13. (Currently amended) The compound of any of claims 1-12 claim 1, wherein R^{6a} is hydrogen.
- 14. (Currently amended) The compound of any of claims 1-12 claim 1, wherein R^{7a} is hydrogen or an optionally substituted C_1 - C_6 alkyl.
- 15. (Currently amended) The compound of any of claims 1-12 and 14 claim 1, wherein R^{7a} is hydrogen or methyl.
- 16. (Currently amended) The compound of any of claims 1-12 and 14-15 claim 1, wherein R^{7a} is hydrogen.
 - 17. (Currently amended) The compound of any of claims 1-12 claim 1, wherein R^{7a}

National Stage of PCT/US2005/07867

Filed : Herewith

is methyl.

18. (Currently amended) The compound of any of claims 1-12 and 14-15 claim 1, wherein R^{6a} and R^{7a} together form a carbonyl.

- 19. (Currently amended) The compound of any of claims 1-18 claim 1, wherein R¹⁰ is selected from among hydrogen, F, Cl, OR^A, an optionally substituted C₁-C₆ alkyl, an optionally substituted C₁-C₆ heterohaloalkyl and (CH₂)_mR^C.
- 20. (Currently amended) The compound of any of claims 1-18 claim 1, wherein R¹⁰ is hydrogen.
- 21. (Currently amended) The compound any of claims 1-20 claim 1, wherein R^9 is selected from among hydrogen, F, Cl, Br, I, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, COR^A , CO_2R^A , $CH(R^D)OR^A$, and $CH(R^D)NR^AR^B$.
- 22. (Currently amended) The compound of any of claims 1-21 claim 1, wherein R^9 is hydrogen, formyl, hydroxy C_1 - C_6 alkyl, hydroxyhalo C_1 - C_6 alkyl, C_1 - C_6 alkylsilyloxy C_1 - C_6 alkyl, C_1 - C_6 alkoxycarbonyl, amino C_1 - C_6 alkyl, carboxy, or C_1 - C_6 alkylcarbonyloxy C_1 - C_6 alkyl.
- 23. (Currently amended) The compound of any of claims 1-22 claim 1, wherein R⁹ is hydrogen, formyl, hydroxymethyl, 1-hydroxy-2,2,2-trifluoromethyl, tributylsilyloxymethyl, ethoxycarbonyl, aminomethyl, carboxy, or acetyoxymethyl.
- 24. (Currently amended) The compound of any of claims 1-23 claim 1, wherein R^{12} and R^{13} are each independently selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heterohaloalkyl and $(CH_2)_m R^C$.
- 25. (Currently amended) The compound of any of claims 1-24 claim 1, wherein R¹³ is hydrogen, F, OH or benzyl.
- 26. (Currently amended) The compound of any of claims 1-25 claim 1, wherein the compound has formula IIA:

-10-

National Stage of PCT/US2005/07867

Filed : Herewith

$$R^{3}$$
 R^{6a}
 R^{7a}
 R^{12}
 R^{13}
 R^{2}
 R^{10}
 R^{9}

27. (Currently amended) The compound of any of claims 1-26 claim 1, wherein the compound has formula IIB:

$$R^{2}$$
 R^{3}
 R^{12}
 R^{12}
 R^{12}
 R^{13}
 R^{12}

28. (Currently amended) The compound of any of claims 1-27 claim 1, wherein R¹ is selected from among NO₂ and CN;

 R^2 is hydrogen, optionally substituted C_1 - C_4 alkyl or an optionally substituted C_1 - C_4 haloalkyl;

 R^3 , R^4 , and R^5 are each independently selected from among hydrogen, F, Cl, and an optionally substituted C_1 - C_4 alkyl;

 R^{6a} and R^{7a} are each independently selected from <u>among</u> hydrogen and an optionally substituted C_1 - C_6 alkyl; an optionally substituted C_1 - C_6 heterohaloalkyl, or R^{6a} and R^{7a} together form a carbonyl;

 R^9 is selected from <u>among</u> hydrogen, F, Cl, Br, I, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, COR^A , CO_2R^A , $CH(R^D)OR^A$, and $CH(R^D)NR^AR^B$;

R¹⁰ is hydrogen; and

 R^{12} and R^{13} are each independently selected from <u>among</u> hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heterohaloalkyl and $(CH_2)_m R^C$.

Applicant: Zhi et al. Attorney's Docket No.: 18202-028US1 / 1112US

Serial No. : To Be Assigned Preliminary Amendment
National Stage of PCT/US2005/07867

Filed : Herewith

29. (Currently amended) The compound of any of claims 1-28 claim 1, wherein R¹ is selected from among NO₂ and CN;

R² is hydrogen or trifluoromethyl;

R³, R⁴, are R⁵ each hydrogen;

R^{7a} is hydrogen or methyl and R^{6a} is hydrogen; or R^{6a} and R^{7a} together form a carbonyl;

R⁹ is selected from <u>among</u> hydrogen, formyl, hydroxymethyl, 1-hydroxy-2,2,2-trifluoromethyl, tributylsilyloxymethyl, ethoxycarbonyl, aminomethyl, carboxy, and acetyoxymethyl

R¹⁰ is hydrogen;

R¹² is hydrogen; and

R¹³ is selected from among hydrogen, F, OH and benzyl.

30. (Original) The compound of claim 1, wherein the compound has formula:

$$R^{7a}$$
 R^{7a}
 R^{7a}

- 31. (Original) The compound of claim 30, wherein R^{7a} is an optionally substituted C_1 - C_6 heterohaloalkyl.
- 32. (Original) The compound of claim 30, wherein R^9 is an optionally substituted C_1 - C_6 heterohaloalkyl.
- 33. (Original) The compound of claim 30, wherein R^{13} is an optionally substituted C_1 - C_6 heterohaloalkyl.

Applicant: Zhi et al. Attorney's Docket No.: 18202-028US1 / 1112US

Serial No. : To Be Assigned Preliminary Amendment
National Stage of PCT/US2005/07867

Filed : Herewith

34. (Original) The compound of claim 30, wherein the compound has formula:

$$R^{7a}$$
 R^{7a}
 R^{7a}

35. (Original) The compound of claim 30, wherein the compound has formula:

$$R^{7a}$$
 R^{7a}
 R^{7a}

36. (Currently amended) The compound of any of claims 1-25 claim 1, wherein the compound has Formula IIC or Formula IID:

$$R^{6a}$$
 R^{7a}
 R^{12}
 R^{13}
 R^{6a}
 R^{7a}
 R^{12}
 R^{13}
 R^{6a}
 R^{7a}
 R^{12}
 R^{13}
 R^{13}
 R^{14}
 R^{10}
 R^{15}
 R^{10}
 R^{10}
 R^{10}
 R^{10}

- 37. (Currently amended) The compound of claim 36, wherein R^1 is NO_2 ; R_2 is hydrogen or haloalkyl; R^3 , R^4 , R^5 , R^{6a} , R^{7a} , R^9 , R^{12} , and R^{13} are each hydrogen; and R^9 is selected from among CO_2R^A , $CH(R^D)OR^A$, and $CH(R^D)NR^AR^B$.
 - 38. (Currently amended) The compound of any of claims 36 or 37 claim 36, wherein

National Stage of PCT/US2005/07867

Filed : Herewith

 R^1 is NO_2 ; R_2 is hydrogen or trifluoromethyl; R^3 , R^4 , R^5 , R^{6a} , R^{7a} , R^9 , R^{12} , and R^{13} are each hydrogen; and R^9 is selected from among hydroxymethyl, ethoxycarbonyl and acetyoxymethyl.

39. (Currently amended) The compound of any of claims 1-2 claim 1, wherein the compound has formula:

$$R^{16}$$
 R^{16}
 R^{16}
 R^{17}
 R^{12}
 R^{13}
 R^{13}
 R^{14}
 R^{17}

40. (Currently amended) The compound of any of claims 1-2 and 39 claim 1, wherein the compound has formula:

$$R^{16}$$
 R^{16}
 R^{16}
 R^{10}
 R^{12}
 R^{13}
 R^{12}
 R^{13}

41. (Currently amended) The compound of any of claims 1-2, 39 and 40 claim 1, wherein the compound has formula:

Applicant: Zhi et al. Attorney's Docket No.: 18202-028US1 / 1112US
Serial No.: To Be Assigned Preliminary Amendment

National Stage of PCT/US2005/07867

Filed : Herewith

$$R^{16}$$
 R^{16}
 R^{16}
 R^{17}
 R^{12}
 R^{13}
 R^{13}

42. (Currently amended) The compound of claim 1, wherein the compound has Formula V or Formula VI:

$$R^{19}$$
 R^{19}
 R^{19}
 R^{18}
 R^{21}
 R^{26}
 R^{25}
 R^{25}
 R^{18}
 R^{18}
 R^{21}
 R^{26}
 R^{25}
 R^{25}
 R^{18}
 R^{21}
 R^{25}
 R^{25}
 R^{25}
 R^{25}
 R^{25}

wherein R¹⁸ and R¹⁹ are each independently selected from <u>among</u> hydrogen, F, Cl, Br, I, OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, an optionally substituted C₁-C₄ heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B;

 R^{20} and R^{21} are each independently selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl; wherein if R^{18} is NO_2 and X is O, then at least one of R^{19} , R^{20} , and R^{21} is not hydrogen, and wherein if R^{19} is NO_2 and X is C, then at least one of R^{18} , R^{20} , and R^{21} is not hydrogen;

 R^{22} is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, COR^6 , CO_2R^A , $CONR^AR^B$, SO_2R^A , an optionally substituted aryl, an optionally substituted heteroaryl, $CH_2CH(R^D)OR^A$, $CH_2CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$, wherein the optionally substituted aryl or optionally substituted heteroaryl is optionally substituted with a substituent selected from among F, Cl, Br, I, CN, OR^A , NO_2 , NR^AR^B , SR^A , SOR^A , SO_2R^A , an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4

National Stage of PCT/US2005/07867

Filed : Herewith

heteroalkyl;

 R^{23} and R^{24} are each independently selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted C_2 - C_8 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, $CH(R^D)OR^A$, $CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$; or R^{23} and R^{24} together form a carbonyl group, provided that if R^{18} is NO_2 and X is NH, then R^{23} and R^{24} do not together form a carbonyl group; or

R²² and R²³ are optionally linked to form a ring; or

R²³ and R²⁵ are optionally linked to form a ring;

 R^{25} is selected from among a halogen, OR^A , NR^AR^B , hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heterohaloalkenyl, an optionally substituted C_2 - C_8 heterohaloalkynyl, an optionally substituted C_2 - C_8 heterohaloalkynyl, an optionally substituted heteroaryl, and $(CH_2)_mR^C$;

X is selected from among O, S, CRARB, NRD, and a bond;

wherein if X is CR^AR^B or a bond, then R^{25} and R^{26} are each independently selected from among a halogen, OR^A , NR^AR^B , hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_1 - C_8 heterohaloalkynyl, an optionally substituted C_2 - C_8 heterohaloalkenyl, an optionally substituted C_2 - C_8 heterohaloalkenyl, an optionally substituted aryl, an optionally substituted aryl, an optionally substituted heteroaryl, and $(CH_2)_mR^C$; or R^{25} and R^{26} together form a carbonyl group;

and wherein if X is O, S, or NRD, then R25 and R26 are each independently selected

National Stage of PCT/US2005/07867

Filed : Herewith

from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, and $(CH_2)_m R^C$; or R^{25} and R^{26} together form a carbonyl group;

 R^A and R^B are each independently selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from <u>among</u> an optionally substituted aryl and an optionally substituted heteroaryl that is optionally with a substituent selected from <u>among</u> F, Cl, Br, I, CN, OR^{A} , NO_{2} , $NR^{A}R^{B}$, SR^{A} , SOR^{A} , $SO_{2}R^{A}$, an optionally substituted C_{1} - C_{4} alkyl, an optionally substituted C_{1} - C_{4} heteroalkyl;

 R^D is selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

Z is selected from among O, S, CRARB, and NRD;

n is 0, 1, or 2; and

m is 1 or 2.

43. (Currently amended) The compound of elaims 1 or 42 claim 1, wherein the compound has Formula VI:

44. (Currently amended) The compound of any of claims 1, and 42-43 claim 1, wherein the compound has Formula:

National Stage of PCT/US2005/07867

Filed : Herewith

$$R^{19}$$
 R^{18}
 R^{21}
 R^{26}
 R^{25}

45. (Currently amended) The compound of any of claims 1 or 43 claim 1, wherein the compound has Formula V:

$$R^{19}$$
 R^{19}
 R^{18}
 R^{21}
 R^{26}
 R^{25}

- 46. (Currently amended) The compound of any of claims 1 and 42 45 claim 1, wherein R^{18} and R^{19} are each independently selected from among hydrogen, NO_2 , and an optionally substituted C_1 - C_4 alkyl; R^{22} is hydrogen, an optionally substituted C_1 - C_4 alkyl; R^{23} and R^{24} are each independently hydrogen or an optionally substituted C_1 - C_4 alkyl; and R^{25} and R^{26} are each hydrogen.
- 47. (Currently amended) The compound of any of claims 1 and 42-46 claim 1, wherein R¹⁸ is NO₂.
- 48. (Currently amended) The compound of any of claims 1 and 42-46 claim 1, wherein R^{19} is NO_2 .
- 49. (Currently amended) The compound of any of claims 1 and 42-45 claim 1, wherein R^{22} is hydrogen, heterohaloalkyl or haloalkyl.
- 50. (Currently amended) The compound of any of claims 1, 42-46 and 49 claim 1, wherein R^{22} is hydrogen or trifluoroethyl.
- 51. (Currently amended) The compound of any of claims 1 and 42-46 claim 1, wherein R^{23} and R^{24} are each independently hydrogen or methyl.
 - 52. (Original) The compound of claim 1, wherein the compound has FormulaVI:

National Stage of PCT/US2005/07867

Filed : Herewith

$$R^{19}$$
 R^{19}
 R^{18}
 R^{21}
 R^{25}

53. (Original) The compound of claim 52, wherein R¹⁸ is NO₂.

54. (Original) The compound of claim 53, wherein R¹⁹ is NO₂.

55. (Original) The compound of claim 52, wherein R^{22} is hydrogen, haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl or an optionally substituted C_1 - C_4 heterohaloalkyl.

56. (Currently amended) The compound of any of claims 52 or 55 claim 52, wherein R²² is hydrogen or trifluoroethyl.

57. (Original) The compound of claim 52, wherein R^{23} is hydrogen, an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted C_1 - C_4 alkyl.

58. (Currently amended) The compound of any of claims 1 or 52 claim 1, wherein R²⁵ is hydrogen, methyl or methoxyphenyl.

59. (Currently amended) The compound of claim 1, wherein the compound has Formula III:

$$R^{16}$$
 R^{16}
 R^{16}
 R^{16}
 R^{16}
 R^{16}
 R^{16}
 R^{10}
 R^{10}
 R^{10}
 R^{10}
 R^{10}

where R^1 and R^2 are each independently selected from <u>among</u> hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$, $NHCOR^A$, and $NHCONR^AR^B$, provided that at least one of R^1 and R^2 is not hydrogen;

 R^{3a} , R^4 , and R^5 are each independently selected from <u>among</u> hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

wherein if R^1 is NO_2 and R^{3a} is F, then at least one of R^2 and R^4 and R^5 is not hydrogen;

R⁶, R⁷, R¹⁰, and R¹¹ are each independently selected from among hydrogen, an

National Stage of PCT/US2005/07867

Filed: Herewith

optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 haloalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^8 and R^9 are each independently selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heterohaloalkyl, an optionally substituted C_2 - C_8 heterohaloalkenyl, an optionally substituted C_2 - C_8 heterohaloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, C_8 - C_8 -

R¹⁴ and R¹⁵ are each independently selected from among hydrogen, F, Cl, Br, I, OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, an optionally substituted C₁-C₄ heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B;

 R^{16} and R^{17} are each independently selected from among hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

 R^A and R^B are each independently selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from <u>among</u> an optionally substituted aryl and an optionally substituted heteroaryl that is optionally with a substituent selected from <u>among</u> F, Cl, Br, I, CN, OR^{A} , NO_{2} , $NR^{A}R^{B}$, SR^{A} , SOR^{A} , $SO_{2}R^{A}$, an optionally substituted C_{1} - C_{4} alkyl, an optionally substituted C_{1} - C_{4} heteroalkyl;

 R^D is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl; and m is 1 or 2;

wherein the compound is selected with a proviso that at least one of R^6 , R^7 , R^{10} , and R^{11} is other than hydrogen and at least one of R^8 and R^9 is other than hydrogen, alkyl, haloalkyl, alkenyl, and alkynyl.

60. (Original) The compound of claim 59, wherein the compound is selected with a

National Stage of PCT/US2005/07867

Filed : Herewith

proviso that at least one of R^6 , R^7 , R^{10} , and R^{11} is other than hydrogen and at least one of R^8 and R^9 is heterohaloalkyl.

61. (Currently amended) The compound of claim 1, wherein the compound has Formula I:

$$R^{3a}$$
 R^{6}
 R^{7}
 R^{8}
 R^{9}
 R^{10}
 R^{10}

wherein R^1 and R^2 are each independently selected from among hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$, $NHCOR^A$, and $NHCONR^AR^B$, provided that at least one of R^1 and R^2 is not hydrogen;

 R^{3a} , R^4 , and R^5 are each independently selected from <u>among</u> hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

wherein if R^1 is NO_2 and R^{3a} is F, then at least one of R^2 and R^4 and R^5 is not hydrogen;

 R^6 , R^7 , R^{10} , and R^{11} are each independently selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^8 and R^9 are each independently selected from among hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally

National Stage of PCT/US2005/07867

Filed : Herewith

substituted heteroaryl, CH(R^D)OR^A, CH(R^D)NR^AR^B, and (CH₂)_mR^C;

 R^A and R^B are each independently selected from <u>among</u> hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from <u>among</u> an optionally substituted aryl and an optionally substituted heteroaryl that is optionally with a substituent selected from <u>among</u> F, Cl, Br, I, CN, OR^{A} , NO_{2} , $NR^{A}R^{B}$, SR^{A} , SOR^{A} , $SO_{2}R^{A}$, an optionally substituted C_{1} - C_{4} alkyl, an optionally substituted C_{1} - C_{4} haloalkyl, and an optionally substituted C_{1} - C_{4} heteroalkyl;

 R^D is selected from among hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl; and m is 1 or 2,

the compound is selected with a proviso that at least one of R^6 , R^7 , R^{10} , and R^{11} is other than hydrogen and at least one of R^8 and R^9 is heterohaloalkyl.

62. (Currently amended) A compound according to of claim 1, wherein the compound is selected from among the group of:

N,N-bis(2,2,2-trifluoroethyl)-3-methyl-4-nitroaniline (compound 101);

N.N-bis(2,2,2-trifluoroethyl)-4-nitroaniline (compound 102);

4-(Bis(2,2,2-trifluoroethyl)amino)-2-(trifluoromethyl)benzonitrile (compound 103);

(5*R*)-*N*-(4-nitrophenyl)-5-(dimethyl-tert-butylsilyloxymethyl)-2-pyrrolidone (compound 104);

(5R)-N-(4-nitrophenyl)-5-(hydroxymethyl)-2-pyrrolidone (compound 105);

(2*R*)-*N*-(4-nitro-3-trifluoromethylphenyl)-2-(dimethyl-tert-butylsilyloxymethyl)pyrrolidine (compound 106);

(2R)-N-(4-nitro-3-trifluoromethylphenyl)-2-(hydroxymethyl)pyrrolidine (compound 108);

(2R)-N-(4-nitrophenyl)-2-(hydroxymethyl)pyrrolidine (compound 109);

(2R)-N-(3-Trifluoromethyl-4-nitrophenyl)-2-formylpyrrolidine (compound 110);

(2*R*)-*N*-(3-Trifluoromethyl-4-nitrophenyl)-2-(1-(*S*)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 111);

(2R)-N-(3-Trifluoromethyl-4-nitrophenyl)-2-(1-(R)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 112);

(2S)-N-(4-nitrophenyl)-2-(hydroxymethyl)pyrrolidine (compound 113);

(2R)-N-(4-nitrophenyl)-2-(1-(S)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 114);

National Stage of PCT/US2005/07867

Filed: Herewith

(2R)-*N*-(4-nitrophenyl)-2-(*R*)-(1-(*R*)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 115);

- (2S)-N-(4-nitrophenyl)-2-(1-(S)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 116);
- (2S)-N-(4-nitrophenyl)-2-(1-(R)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 117);
- 3-(3-Methoxyphenyl)-6-nitro-2,7-dimethyl-1H-indole (compound 118);
- 4-[Bis-(2,2,2-trifluoroethyl)amino]-2-chloro-3-methyl-benzonitrile (compound 119);
- cis-2,5-Dimethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 120);
- trans-2,5-dimethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 121);
- 1-(4-Nitro-3-trifluoromethylphenyl)-piperidine-2-carboxylic acid ethyl ester (compound 122);
- 1-(4-Nitro-3-trifluoromethylphenyl)-4-(hydroxymethyl)-piperidine (compound 123);
- (1-(3-trifluoromethyl-4-nitrophenyl)piperidin-2-yl)methyl acetate (compound 124);
- 4-(2-Hydroxymethyl-pyrrolidin-1-yl)-benzonitrile (compound 125);
- 4-Benzyl-2-hydroxymethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 126);
- 2-Fluoro-4-(2-hydroxymethyl-pyrrolidin-1-yl)-benzonitrile (compound 127);
- 4-Hydroxy-1-(4-nitrophenyl)-pyrrolidine-2-carboxylic acid ethyl ester (compound 128);
- 4-Hydroxy-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine-2-carboxylic acid ethyl ester (compound 129);
- 5-Hydroxymethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidin-3-ol (compound 130);
- 2-(Aminomethyl)-1-(4-Nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 131);
- 4-Hydroxy-1-(4-nitrophenyl)-pyrrolidine-2-carboxylic acid (compound 132); and
- 4-Hydroxy-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine-2-carboxylic acid (compound 133);

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

- 63. (Currently amended) The compound according to any of claims 1-62 of claim 1, wherein the compound is a selective androgen receptor modulator.
- 64. (Currently amended) The selective androgen receptor modulator according to of claim 63, wherein the compound is an androgen receptor agonist.
- 65. (Currently amended) The selective androgen receptor modulator according to of claim 63, wherein the compound is an androgen receptor antagonist.
- 66. (Currently amended) The selective androgen receptor modulator according to of claim 63, wherein the compound is an androgen receptor partial agonist.

National Stage of PCT/US2005/07867

Filed : Herewith

67. (Currently amended) The selective androgen receptor modulator according to of claim 63, wherein the compound is a tissue-specific modulator.

- 68. (Currently amended) The compound according to any of claims 1-62 of claim 1, wherein the compound is a selective androgen binding compound.
- 69. (Currently amended) A method for modulating an activity of an androgen receptor, comprising contacting an androgen receptor with a compound according to any of claims 1-62 of claim 1.
 - 70. (Original) The method of claim 68, wherein the androgen receptor is in a cell.
- 71. (Currently amended) A method for identifying a compound that is capable of modulating an activity of an androgen receptor comprising:

contacting a cell expressing an androgen receptor with a compound according to any of claims 1-62 of claim 1; and

monitoring an effect of the compound upon the cell.

- 72. (Currently amended) A method for treating a patient having a condition susceptible to treatment with an androgen receptor modulator, comprising administering to the patient a pharmaceutical agent comprising a compound according to any of claims 1-62 of claim 1.
- 73. (Currently amended) The method of claim 72, wherein the condition is selected from among maintenance of muscle strength and function; reversal or prevention of frailty or age-related functional decline in the elderly; treatment of catabolic side effects of glucocorticoids; treatment of reduced bone mass, density or growth; treatment of chronic fatigue syndrome; chronic myalgia; treatment of acute fatigue syndrome and muscle loss; accelerating of wound healing; accelerating bone fracture repair; accelerating healing of complicated fractures; in joint replacement; prevention of post-surgical adhesion formation; acceleration of tooth repair or growth; maintenance of sensory function; treatment of periodontal disease; treatment of wasting secondary to fractures and treatment of wasting in connection with chronic obstructive pulmonary disease, treatment of wasting in connection with chronic liver disease, treatment of wasting in connection with AIDS, cancer cachexia, burn and trauma recovery, chronic catabolic state, eating disorders and chemotherapy; treatment of cardiomyopathy; treatment of thrombocytopenia; treatment of growth retardation in connection with Crohn's disease; treatment of short bowel syndrome; treatment of irritable bowel syndrome; treatment of inflammatory bowel disease; treatment of Crohn's disease and

National Stage of PCT/US2005/07867

Filed: Herewith

ulcerative colits; treatment of complications associated with transplantation; treatment of physiological short stature including growth hormone deficient children and short stature associated with chronic illness; treatment of obesity and growth retardation associated with obesity; treatment of anorexia; treatment of hypercortisolism and Cushing's syndrome; Paget's disease; treatment of osteoarthritis; induction of pulsatile growth hormone release; treatment of osteochondro-dysplasias; treatment of depression, nervousness, irritability and stress; treatment of reduced mental energy and low self-esteem; improvement of cognitive function; treatment of catabolism in connection with pulmonary dysfunction and ventilator dependency; treatment of cardiac dysfunction; lowering blood pressure; protection against ventricular dysfunction or prevention of reperfusion events; treatment of adults in chronic dialysis; reversal or slowing of the catabolic state of aging; attenuation or reversal of protein catabolic responses following trauma; reducing cachexia and protein loss due to chronic illness; treatment of hyper-insulinemia; treatment of immunosuppressed patients; treatment of wasting in connection with multiple sclerosis or other neurodegenerative disorders; promotion of myelin repair; maintenance of skin thickness; treatment of metabolic homeostasis and renal homeostasis; stimulation of osteoblasts, bone remodeling and cartilage growth; regulation of food intake; treatment of insulin resistance; treatment of insulin resistance in the heart; treatment of hypothermia; treatment of congestive heart failure; treatment of lipodystrophy; treatment of muscular atrophy; treatment of musculoskeletal impairment; improvement of the overall pulmonary function; treatment of sleep disorders; and the treatment of the catabolic state of prolonged critical illness; treatment of hirsutism, acne, seborrhea, androgenic alopecia, anemia, hyperpilosity, benign prostate hypertrophy, adenomas and neoplasies of the prostate and malignant tumor cells containing the androgen receptor; osteosarcoma; hypercalcemia of malignancy; metastatic bone disease; treatment of spermatogenesis, endometriosis and polycystic ovary syndrome; conteracting counteracting preeclampsia, eclampsia of pregnancy and preterm labor; treatment of premenstural premenstrual syndrome; treatment of vaginal dryness; age related decreased testosterone levels in men, male menopause, hypogonadism, male hormone replacement, male and female sexual dysfunction, male and female contraception, hair loss, Reaven's Syndrome and the enhancement of bone and muscle strength.

74. (Currently amended) A method according to claim 72, wherein the patient has a condition selected from among the group of acne, male-pattern baldness, wasting diseases,

National Stage of PCT/US2005/07867

Filed : Herewith

hirsutism, hypogonadism, osteoporoses, infertility, impotence and cancer.

75. (Currently amended) A method for stimulating hematopoiesis in a patient, comprising administering to the patient a pharmaceutical agent comprising a compound according to any of claims 1-62 of claim 1.

- 76. (Currently amended) A method of contraception, comprising administering to patient a pharmaceutical agent comprising a compound according to any of claims 1-62 of claim 1.
- 77. (Currently amended) A method of improving athletic performance in an athlete, comprising administering to the athlete a pharmaceutical agent comprising a compound according to any of claims 1-62 of claim 1.
- 78. (Currently amended) A pharmaceutical composition, comprising a compound of claims 1-62 of claim 1 and a pharmaceutical acceptable carrier.

Claims 79-81 (Cancelled).

82. (Currently amended) An article of manufacture, comprising: packaging material; [[,]]

a compound of any of claims 1-62 which of claim 1 that is effective for modulating the activity of androgen receptor, or for treatment, prevention or amelioration of one or more symptoms of androgen receptor mediated diseases or disorders, or diseases or disorders in which androgen receptor activity is implicated, within the packaging material; [[,]] and

a label that indicates that the compound or composition, or pharmaceutically acceptable derivative thereof, is used for modulating the activity of androgen receptor or for treatment, prevention or amelioration of one or more symptoms of androgen receptor mediated diseases or disorders, or diseases or disorders in which androgen receptor activity is implicated.